Cargando…

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis

BACKGROUND: Triple negative breast cancer (TNBC) is a highly heterogeneous and aggressive disease, and although no effective targeted therapies are available to date, about one-third of patients with TNBC achieve pathologic complete response (pCR) from standard-of-care anthracycline/taxane (ACT) che...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Tingting, Shi, Weiwei, Wali, Vikram B., Pongor, Lőrinc S., Li, Charles, Lau, Rosanna, Győrffy, Balázs, Lifton, Richard P., Symmans, William F., Pusztai, Lajos, Hatzis, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154510/ https://www.ncbi.nlm.nih.gov/pubmed/27959926 http://dx.doi.org/10.1371/journal.pmed.1002193

Ejemplares similares

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer
por: Jiang, Tingting, et al.
Publicado: (2014)

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
por: Marczyk, Michal, et al.
Publicado: (2020)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
por: Menyhárt, Otília, et al.
Publicado: (2019)

Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations
por: Patwardhan, Gauri A., et al.
Publicado: (2021)

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
por: Marczyk, Michal, et al.
Publicado: (2019)

A snapshot of 3649 Web-based services published between 1994 and 2017 shows a decrease in availability after 2 years
por: Ősz, Ágnes, et al.
Publicado: (2017)

Currently favored sampling practices for tumor sequencing can produce optimal results in the clinical setting
por: Pongor, Lőrinc S., et al.
Publicado: (2020)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer
por: Nagy, Ádám, et al.
Publicado: (2016)

Cell Dispersal Influences Tumor Heterogeneity and Introduces a Bias in NGS Data Interpretation
por: Pongor, Lőrinc, et al.
Publicado: (2017)

Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples
por: Fu, Chunxiao, et al.
Publicado: (2021)

Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes
por: Menyhart, Otília, et al.
Publicado: (2019)

Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
por: Popovici, Vlad, et al.
Publicado: (2010)

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity
por: Shi, Weiwei, et al.
Publicado: (2018)

Functional germline variants as potential co-oncogenes
por: Agarwal, Divyansh, et al.
Publicado: (2017)

Fast and Sensitive Alignment of Microbial Whole Genome Sequencing Reads to Large Sequence Datasets on a Desktop PC: Application to Metagenomic Datasets and Pathogen Identification
por: Pongor, Lőrinc S., et al.
Publicado: (2014)

Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer
por: Bottai, Giulia, et al.
Publicado: (2017)

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Munkácsy, Gyöngyi, et al.
Publicado: (2023)

Dynamic classification using case-specific training cohorts outperforms static gene expression signatures in breast cancer
por: Győrffy, Balázs, et al.
Publicado: (2015)

Control of dataset bias in combined Affymetrix cohorts of triple negative breast cancer
por: Karn, Thomas, et al.
Publicado: (2014)

Novel Functional Assay for Spindle-Assembly Checkpoint by Cyclin-Dependent Kinase Activity to Predict Taxane Chemosensitivity in Breast Tumor Patient
por: Torikoshi, Yasuhiro, et al.
Publicado: (2013)

Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer
por: Pálinkás, Hajnalka Laura, et al.
Publicado: (2022)

Different mutations in SARS-CoV-2 associate with severe and mild outcome
por: Nagy, Ádám, et al.
Publicado: (2021)

Exploring the Significance of the Exon 4-Skipping Isoform of the ZNF217 Oncogene in Breast Cancer
por: Bellanger, Aurélie, et al.
Publicado: (2021)

Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers
por: Masuda, Hiroko, et al.
Publicado: (2013)

Monitoring the Antioxidant Mediated Chemosensitization and ARE-Signaling in Triple Negative Breast Cancer Therapy
por: Foygel, Kira, et al.
Publicado: (2015)

PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim
por: Byerly, Jessica H., et al.
Publicado: (2020)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
por: Li, Qiyuan, et al.
Publicado: (2011)

TP53 mutation hits energy metabolism and increases glycolysis in breast cancer
por: Harami-Papp, Hajnalka, et al.
Publicado: (2016)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer
por: Jacot, William, et al.
Publicado: (2020)

The Bimodality Index: A Criterion for Discovering and Ranking Bimodal Signatures from Cancer Gene Expression Profiling Data
por: Wang, Jing, et al.
Publicado: (2009)

A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy
por: Shen, Kui, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1i4uv26kiapkrk6e75dfabs6ud